Kerry Oliver, Ph.D.

President, Chief Scientific Officer

Dr. Kerry Oliver has over thirty years of academic, government, and industry experience in assay development. This work has spanned a broad range of disciplines including immunology and signal transduction biochemistry, diagnostic device development, and CRO services supporting various stages of therapeutic development. Following his Ph.D. in immunology from The University of Texas Southwestern Medical Center at Dallas, under the direction of Dr. Ellen Vitetta, Kerry received his postdoctoral training examining signal transduction pharmacology at the National Institutes of Health. Subsequently, Kerry spent three years in drug discovery.

In 1997, Kerry joined the R&D department at Luminex during its initial development of the xMAP® diagnostic platform. His initial responsibility at Luminex was to lead a team of assay development scientists to showcase the capabilities of the platform to early adopters of xMAP technology. In addition, he served as a liaison with key customers and strategic partners to expedite their adoption and commercialization of the platform.

In late 2001, Kerry founded Radix BioSolutions to satisfy unmet customer needs with custom molecular and immunoassay development, validation, and manufacturing. Radix products are used for customer’s in-house research, clinical trials, and environmental threat assessment and testing.